Free tool
FAERS Monitor: Lantus Solostar
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 021081 or its brand name (Lantus Solostar, Insulin Glargine Recombinant). Reports on generic versions are filed under their own applications.
Reports
202,872
Serious
112,860
56% of reports
Hospitalization
58,331
Death reported
12,531
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- blood glucose increased29,554
- off label use13,004
- nausea8,711
- drug ineffective8,451
- inappropriate schedule of product administration8,366
- blood glucose decreased8,334
- hypoglycaemia7,179
- product storage error6,908
- visual impairment6,568
- diarrhoea6,177
- fatigue6,032
- dyspnoea5,652
- malaise5,651
- weight decreased5,645
- vomiting5,587
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1,035 |
| 2005 | 1,804 |
| 2006 | 3,270 |
| 2007 | 3,327 |
| 2008 | 2,949 |
| 2009 | 3,916 |
| 2010 | 5,398 |
| 2011 | 6,269 |
| 2012 | 5,590 |
| 2013 | 8,148 |
| 2014 | 12,103 |
| 2015 | 18,871 |
| 2016 | 12,475 |
| 2017 | 11,285 |
| 2018 | 16,789 |
| 2019 | 13,842 |
| 2020 | 11,767 |
| 2021 | 10,694 |
| 2022 | 9,994 |
| 2023 | 8,875 |
| 2024 | 10,646 |
| 2025 | 13,310 |
| 2026 | 10,512 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,851,287 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood glucose decreasedSignal | 8,334 | 21.6 | 21.1 | 135,342 |
| blood glucose increasedSignal | 29,554 | 19.1 | 18.9 | 431,302 |
| hypoglycaemiaSignal | 7,179 | 17.8 | 17.4 | 97,420 |
| product storage errorSignal | 6,908 | 8.8 | 8.6 | 44,144 |
| visual impairmentSignal | 6,568 | 5.7 | 5.6 | 24,526 |
| inappropriate schedule of product administrationSignal | 8,366 | 5.0 | 4.9 | 25,732 |
| weight decreasedSignal | 5,645 | 2.1 | 2.1 | 3,311 |
| off label use | 13,004 | 1.5 | 1.5 | 2,591 |
| malaise | 5,651 | 1.3 | 1.3 | 492 |
| vomiting | 5,587 | 1.2 | 1.2 | 252 |
| nausea | 8,711 | 1.1 | 1.1 | 159 |
| dyspnoea | 5,652 | 1.0 | 1.0 | 7 |
| diarrhoea | 6,177 | 1.0 | 1.0 | 0 |
| fatigue | 6,032 | 0.8 | 0.8 | 305 |
| drug ineffective | 8,451 | 0.7 | 0.6 | 1,538 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.